HomeAI · summaries
Storia in 3 fonti
Jazz turns to AbCellera for T cell engagers against GI cancers in up to $4.1B deal
AbCellera and Jazz Pharmaceuticals strike a preclinical T cell engager deal worth up to $4.1B targeting gastrointestinal and other solid tumor cancers across up to five programs.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Jazz zeroes in on next-gen T cell engagers with AbCellera deal
The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers, which, so far, have had limited success outside of…
- ·
endpoints.news
Jazz turns to AbCellera for T cell engagers against GI cancers in up to $4.1B deal
AbCellera and Jazz Pharmaceuticals strike a preclinical T cell engager deal worth up to $4.1B targeting gastrointestinal and other solid tumor cancers across up to five programs.
